Indications
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. Ivemend 150 mg is given as part of a combination therapy.
Composition
- Active substance
- fosaprepitant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ivemend
- Active substance
- fosaprepitant
- ATC code
- A04AD12
- Therapeutic area
- Vomiting, Cancer
- Marketing authorisation holder
- Merck Sharp & Dohme B.V.
- Status
- Authorised